Bard buys bulking agent from Genyx
This article was originally published in Clinica
CR Bard has exercised its right to acquire a PMA-approved implantable bulking agent for the treatment of stress urinary incontinence. The Murray Hill, New Jersey firm intends to launch Uryx, which it acquired from Genyx Medical, in the first half of 2005. The polymer product is minimally invasively injected into the area around the urethra.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.